LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Akciju saraksts・Simulations Plus Inc

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

15.99 0.88

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

15.65

Max

16.61

Galvenie mērījumi
By Trading Economics
Ienākumi	3.9M 4.5M
Pārdošana	5.9M 24M
EPS	0.35
Peļņas marža	18.669
Darbinieki	212
EBITDA	4.9M 7.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+0.57% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 13. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	70M 321M
Iepriekšējā atvēršanas cena	15.11
Iepriekšējā slēgšanas cena	15.99

Ziņu noskaņojums

By Acuity

95%

314 / 344 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. jūn. 23:49 UTC

Tirgus saruna

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026. g. 9. jūn. 23:45 UTC

Iegādes, apvienošanās, pārņemšana

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026. g. 9. jūn. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026. g. 9. jūn. 23:35 UTC

Tirgus saruna

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026. g. 9. jūn. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026. g. 9. jūn. 20:51 UTC

Peļņas

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 20:09 UTC

Tirgus saruna

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026. g. 9. jūn. 19:36 UTC

Tirgus saruna

Cattle Climbs as Crude Oil Falls -- Market Talk

2026. g. 9. jūn. 19:32 UTC

Tirgus saruna

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026. g. 9. jūn. 19:25 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026. g. 9. jūn. 19:00 UTC

Tirgus saruna

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026. g. 9. jūn. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026. g. 9. jūn. 18:47 UTC

Tirgus saruna

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026. g. 9. jūn. 18:37 UTC

Tirgus saruna

Canada's Cooling Trade With the U.S. -- Market Talk

2026. g. 9. jūn. 18:27 UTC

Tirgus saruna

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026. g. 9. jūn. 17:35 UTC

Tirgus saruna

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026. g. 9. jūn. 17:30 UTC

Tirgus saruna

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026. g. 9. jūn. 16:34 UTC

Tirgus saruna

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 9. jūn. 15:28 UTC

Tirgus saruna

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026. g. 9. jūn. 15:25 UTC

Tirgus saruna

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

0.57% augšup

Prognoze 12 mēnešiem

Vidējais 16 USD 0.57%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

314 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.